Abstract
A silk fibroin hydrolysate (SFH) exhibited a pronounced in vivo blood pressure-lowering effect on spontaneously hypertensive rats (SHRs) accompanied with decreases in the plasma angiotensin II, endothelin (ET), TNF-α and NO concentrations. We also observed a markedly decreased LPO level, a parameter of oxidative tissue damage, in the medium- and high-dose SFH-treated groups which was accompanied by an increased SOD level in erythrocytes. Our data suggest ACE inhibition together with an improved antioxidative status as the underlying antihypertensive mechanism for the silk fibroin hydrolysate. Since SFH could markedly lower the blood pressure and improve several physiological parameters involved in the occurrence of hypertension, it could be used as a possible supplement against cardiovascular diseases and as a functional food ingredient.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
